Pralatrexate-Folotyn

CareFirst Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518.** For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ **Same as Referring Provider** ❑ **Same as Requesting Provider**
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical*	❑ *Home*	❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital*	❑ *Office*	❑ *Pharmacy*

What is the ICD-10 code? _____

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720

CVS Caremark Specialty Pharmacy ● 2211 Sanders Road NBT-6 ● Northbrook, IL 60062
Phone: 1-888-877-0518 ● Fax: 1-855-330-1720 ● www.caremark.com

Criteria Questions:

1. Is this a request for continuation of therapy with the requested drug?
❒ Yes, *Continue to 2*
❒ No, *Continue to 4*

2. What is the diagnosis?
❒ Peripheral T-cell lymphoma (PTCL) (including the following subtypes: anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype, or follicular T-cell lymphoma), *Continue to 3*
❒ Adult T-cell leukemia/lymphoma (ATLL), *Continue to 3*
❒ Mycosis fungoides (MF), *Continue to 3*
❒ Sezary syndrome (SS), *Continue to 3*
❒ Cutaneous anaplastic large cell lymphoma (ALCL), *Continue to 3*
❒ Extranodal NK/T-cell lymphoma, *Continue to 3*
❒ Hepatosplenic T-cell lymphoma, *Continue to 3*
❒ Breast implant-associated anaplastic large cell lymphoma (ALCL), *Continue to 3*
❒ Other, please specify. _____, *Continue to 3*

3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

4. What is the diagnosis?
❒ Peripheral T-cell lymphoma (PTCL) (including the following subtypes: anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype, or follicular T-cell lymphoma), *Continue to 5*
❒ Adult T-cell leukemia/lymphoma (ATLL), *Continue to 7*
❒ Mycosis fungoides (MF), *No further questions*
❒ Sezary syndrome (SS), *No further questions*
❒ Cutaneous anaplastic large cell lymphoma (ALCL), *Continue to 9*
❒ Extranodal NK/T-cell lymphoma, *Continue to 10*
❒ Hepatosplenic T-cell lymphoma, *Continue to 14*
❒ Breast implant-associated anaplastic large cell lymphoma (ALCL), *Continue to 16*

5. Will the requested drug be used as a single agent?
❒ Yes, *Continue to 6*
❒ No, *Continue to 6*

6. What is the clinical setting in which the requested drug will be used?
❒ Relapsed disease, *No further questions*
❒ Refractory disease, *No further questions*
❒ The requested drug will be used for initial palliative therapy, *No further questions*
❒ Other, please specify. _____, *No further questions*

7. Will the requested drug be used as a single agent?

❒ Yes, *Continue to 8*
❒ No, *Continue to 8*

8. What is the place in therapy in which the requested drug will be used?

❒ First-line therapy, *No further questions*

❒ Subsequent therapy, *No further questions*

9. Will the requested drug be used as a single agent?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

10. Will the requested drug be used as a single agent?
❒ Yes, *Continue to 11*
❒ No, *Continue to 11*

11. What is the clinical setting in which the requested drug will be used?

❒ Relapsed disease, *Continue to 12*

❒ Refractory disease, *Continue to 12*

❒ Other, please specify. _____, *Continue to 12*

12. Has the patient had an inadequate response to asparaginase-based therapy (e.g., pegaspargase)?
❒ Yes, *No Further Questions*
❒ No, *Continue to 13*

13. Does the patient have a contraindication to asparaginase-based therapy (e.g., pegaspargase)?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

14. Will the requested drug be used as a single agent?
❒ Yes, *Continue to 15*
❒ No, *Continue to 15*

15. How many previous lines of chemotherapy has the patient received?

_____ *lines, No further questions*

16. Will the requested drug be used as a single agent?
❒ Yes, *Continue to 17*
❒ No, *Continue to 17*

17. What is the place in therapy in which the requested drug will be used?

❒ First-line therapy, *No further questions*

❒ Subsequent therapy, *No further questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Case Review Unit CVS Caremark Specialty Programs Fax: 1-855-330-1720